TV005

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Beth Kirkpatrick

Conditions

Dengue

Phase 1

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

CompletedNCT02317900

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2014-12-31Target: 48Updated: 2017-02-01

Phase 2

Dengue Controlled Human Infection Model in Dhaka, Bangladesh

Active, not recruitingNCT05229354

Beth KirkpatrickDengue

Start: 2021-12-11End: 2025-07-31Updated: 2024-07-17

Related Papers

TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies

Journal of Clinical Investigation2023-11-1623 citations